This study investigated the time-course of the nociceptive neuropeptide substance P and nerve growth factor (NGF), which facilitates substance P production, in lumbar and cervical dorsal root ganglia (DRG) of streptozotocin-induced diabetic rats. Levels of substance P and NGF were measured by radioimmunoassay and sandwich enzyme-linked immunosorbent assay, respectively, 2 months, 4 months and 8 months after induction of diabetes, and compared with age-matched non-diabetic control rats. At 2 months and 4 months, substance P and NGF levels were lower in the lumbar DRG of the diabetic rats than in controls. At 8 months, substance P and NGF were lower in both the lumbar and cervical DRG of the diabetic rats than in controls. These data demonstrate that a decrease in substance P levels in primary sensory neurons with NGF depletion occurs in an axonal length-dependent manner in diabetic rats, and that this decrease may be correlated with the duration of diabetes.
Introduction
Diabetic peripheral polyneuropathy is characterized by distal and sensorydominant nerve dysfunction, 1 often leading to diabetic gangrene and amputation in patients with severe sensory disturbance. The pathogenesis of diabetic polyneuropathy is not fully understood. It may involve metabolic alterations in the polyol pathway 2 or vascular factors. 3 -5 The development of diabetic polyneuropathy may be heterogeneous or involve a complex array of factors, and the principal cause of peripheral nerve dysfunction might depend on the stage of neuropathy. 6 The most clinically problematic symptoms of diabetic neuropathy are sensory disturbances or loss of sensation. Both Aδand C-fibres are specifically activated by nociceptive stimulation in peripheral tissues. Such stimulation is followed by the secretion of neuropeptide substance P from the axon terminals of the proximal end of secondary sensory neurons in the dorsal column of the spinal cord. 7 The neurotransmitter is produced in primary sensory neurons of dorsal root ganglia (DRG) and transported towards central and peripheral terminals by axons. 8 The production of nociceptive neurotransmitters in DRG is promoted by nerve growth factor (NGF), a neurotrophic factor produced in peripheral tissues containing keratinocytes. 9 NGF binds to the high-affinity receptor TrkA and is internalized at axon terminals and transported in a retrograde fashion in the axon to the neuronal cell body. 10 -14 Via a signal cascade, NGF activates specific genes of nociceptive neuropeptide pre-protachykinin A, a substance P precursor. 15 -17 The production of NGF is decreased in peripheral tissues of the hind paws of diabetic rats 18 -20 and retrograde axonal transport is disturbed, 21 -23 lowering production of neuropeptides in lumbar DRG. 24 However, the time-course of the spatial distribution of nociceptive neurotransmitters during diabetes has not been examined. Clinically, pain sensation is impaired primarily in the lower limbs of diabetic patients. Pain sensation in the upper limbs is usually unchanged until the late stage of diabetic peripheral polyneuropathy. To investigate factors underlying this difference in the onset of impaired pain sensation, we examined the spatial distribution of substance P and NGF in an experimental model of diabetes.
Materials and methods

ANIMALS
Eighteen rats with streptozotocin (STZ)-induced diabetes and 18 non-diabetic age-matched rats were used. Protocols describing the use of rats were approved by the Animal Care Committee of Asahikawa Medical College, Japan, and were in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. To induce diabetes, 6-week-old male Crj Wistar rats (body weight, 240 -260 g) were given an intravenous injection of STZ (50 mg/kg body weight; Sigma Chemical Co., St Louis, MO, USA) in 0.01 M citrate buffer (pH 4.5). Rats were considered diabetic if their non-fasting plasma glucose concentration was above 300 mg/dl 2 weeks after the STZ injection. Their non-fasting plasma glucose concentrations were monitored on alternate weeks for the duration of the experiment. If the glucose level was below 300 mg/dl, the animal was excluded from the experiments. Standard Purina rat chow and water were provided ad libitum. The animal room was maintained on a 12-h light/dark cycle. Six rats from each group were sacrificed at either 2 months, 4 months or 8 months after induction of diabetes.
Substance P levels in left-side DRG at C5 -7 (cervical level) and L4 -6 (lumbar level), NGF levels in right-side DRG at C5 -7 and L4 -6, and in fore-and hind-paw skin were measured in six animals from each group at each time-point.
NERVE GROWTH FACTOR MEASUREMENT
The animals were deeply anaesthetized with an intraperitoneal injection of sodium pentobarbital. The left-side DRG at C5 -7 and L4 -6 and the fore-and hind-paw skin (full thickness) were removed and weighed. The specimens were minced and homogenized immediately in 0.17 ml of icecold extraction medium (100 mM trishydrogen chloride, 0.4 M sodium chloride, 1% bovine serum albumin, 0.05% sodium azide, 1% Triton X100, 1 mM phenylmethylsulphonyl fluoride, 4 mM ethylenediaminetetra-acetic acid, 0.09 IU/ml aprotinin, pH 7.0). The homogenized solution was ultracentrifuged at 100 000 g for 30 min at 4°C, and the supernatants stored at -80°C until assay. The materials were then thawed, and the NGF level was measured by sandwich enzyme-linked immunosorbent assay (ELISA) using commercially available materials (anti-NGF antibody no. 1008218, anti-NGF antibody conjugated with βgalactosidase no. 1008234, standard mouse NGF no. 1530631, Roche Diagnostics GmbH, Mannheim, Germany). The lowest detectable level of the assay is 5 pg/ml. All measurements were performed in duplicate, and intra-and inter-assay variations were 3.1% and 2.5%, respectively. The results were expressed as ng/g wet tissue.
SUBSTANCE P MEASUREMENT
The right-side DRG at C5 -7 and L4 -6 were removed and weighed. The materials were boiled for 5 min in 20 µl of double-distilled water, and 150 µl of 2 N acetic acid was added to the solution and homogenized. The solution was ultracentrifuged at 100 000 g for 30 min at 4°C, and the supernatants were stored at -20°C until required. The materials were thawed and substance P immunoreactivities were measured by radioimmunoassay using a commercially available kit (RIA Kit 7451, Boehringer Mannheim, Germany). The lowest detectable level of the assay is 0.1 pg/tube. All measurements were performed in duplicate, and intra-and inter-assay variations were 2.1% and 1.8%, respectively. The results were expressed as ng/g wet tissue.
GLYCATED HAEMOGLOBIN MEASUREMENT
Before sacrificing, the rats were weighed, and 500 µl of blood was taken from the heart. The blood glucose concentration was measured by the glucose oxidase method, 25 and glycated haemoglobin was measured by affinity chromatography (Glyc-Affin GHb, Seikagaku Corp., Tokyo, Japan).
STATISTICAL ANALYSIS
Data are expressed as means ± SE. Statistical analysis was performed by one-way analysis H Kanbayashi, H Itoh, T Kashiwaya et al. Nociceptive neuropeptide in a diabetes model of variance (ANOVA) followed by Fisher's least significant difference. Differences with P < 0.05 were considered statistically significant.
Results
DEVELOPMENT OF DIABETIC STATE
At all time-points after induction of diabetes, body weight was significantly lower (P < 0.01), and the plasma glucose and glycated haemoglobin concentrations were significantly higher (P < 0.01) in the diabetic rats than in the age-matched non-diabetic controls (Fig. 1 ).
NERVE GROWTH FACTOR MEASUREMENT
At 2 months and 4 months after the onset of diabetes, the NGF level at the L4 -6 DRG was significantly lower in the diabetic rats than in the controls (P < 0.05). At 8 months, the NGF levels of DRG at both C5 -7 ( Fig. 2A ) and L4 -6 ( Fig. 2B) were significantly lower in the diabetic rats than in the controls (P < 0.05). In contrast, the NGF levels of fore-and hind-paw skin at 2 months or 4 months did not differ between the diabetic rats and the controls (Fig. 3) . At 8 months, the NGF levels of the fore-and hind-paw skin were significantly lower in the diabetic rats than in the controls (P < 0.05; Fig. 3 ).
SUBSTANCE P MEASUREMENT
A decrease in substance P levels at both the C5 -7 and L4 -6 DRG appeared to be correlated with aging in both groups. At 2 months and 4 months after induction of diabetes, the substance P level of DRG at L4 -6 was significantly lower in the diabetic rats than in the controls (P < 0.05). At 8 months, substance P levels at both C5 -7 and L4 -6 DRG were significantly lower in the diabetic rats than in the controls (P < 0.01; Fig. 4 ).
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Discussion
We demonstrated spatial alterations of the nociceptive neuropeptide substance P in the DRG of diabetic rats. Nociceptive neuropeptide concentrations in DRG at the lumbar level were lower in diabetic rats than in controls 2 months and 4 months after induction of diabetes. At 8 months, the nociceptive neuropeptide concentrations in DRG at both the lumbar and cervical levels in diabetic rats had decreased even further compared with the controls.
Nociceptive neuropeptides play an important role in the transmission of nociception from peripheral tissues to secondary sensory neurons in the dorsal column of the spinal cord. Such transmission occurs via primary sensory nerves originating from DRG. 26 Because diabetes primarily affects pain sensation in the lower extremities, differences between peripheral sensory system nociceptive neuropeptides in the upper limbs and the lower limbs (i.e. differences related to axon length) may provide important clues to understanding the pathogenesis of diabetic peripheral polyneuropathy. Studies have reported that the expression of substance P in lumbar DRG is decreased in experimental models of diabetes. 27 -29 Another study has demonstrated that substance P levels in cervical DRG are decreased in late-stage diabetes. 30 To our knowledge, however, no study has demonstrated independent changes in neuropeptide concentrations of DRG at different spinal levels in diabetic rats. Our results show that nociceptive neuropeptides decreased at lumbar DRG innervating the hind-paw skin early in diabetes. Later in the time-course of the disease, a similar decrease in nociceptive neuropeptides occurred at cervical DRG innervating the fore-paw skin. Our findings are consistent with clinical observations that sensory impairment initially develops in the lower, not upper, limbs of Nerve growth factor is produced at peripheral tissues innervated by sensory and post-ganglionic sympathetic nerves. Keratinocytes of the skin are one of the peripheral sources of NGF. At axon terminals, NGF binds to specific high-affinity receptor TrkA. The NGF-TrkA complex is then internalized, activated and transported in a retrograde manner by dynein motor protein on microtubules in peripheral nerves. The complex is transported to the DRG or 14,31 -35 The production of the nociceptive neuropeptides substance P in DRG depends on NGF. 16, 17, 36 Therefore, we measured NGF levels in the fore-and hindpaw skin as well as in the DRG. Our results showed no decrease in the NGF level of the skin of either paw at either 2 months or 4 months after diabetes induction. At this time, however, the levels of NGF and the nociceptive neuropeptide in lumbar DRGs were already lower than the respective control values. At 8 months, NGF levels in both lumbar and cervical DRG were significantly lower than in the controls; further, NGF concentrations of fore-and hind-paw skin were significantly lower than in the controls. In experimental and human diabetes, impaired peripheral production, 37 uptake and retrograde axonal transport of NGF have been reported. 21, 23, 38, 39 Schmidt et al. 22 demonstrated that retrograde axonal transport of NGF in mesenteric nerves of STZinduced diabetic rats decreased significantly as early as several days after the induction of diabetes. In contrast, the production of NGF in the skin was reported to be impaired in humans with long-standing diabetes. 18 Although many previous studies have provided evidence of impaired NGF function, the mechanisms involved, most important sites, and timing of changes in NGF concentrations have yet to be determined. Our data suggest that disturbed retrograde axonal transport of NGF may precede NGF depletion in peripheral tissues.
We conclude that the spatial distribution of nociceptive neuropeptide substance P depends on NGF depletion in the peripheral nervous system of rats with STZ-induced diabetes. These findings also suggest that NGF appears to be one of the factors involved in the complex pathogenesis of diabetic peripheral polyneuropathy. 
